12 results on '"de Gruijl, Tanja D."'
Search Results
2. Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy
- Author
-
van de Ven, Rieneke, Reurs, Anneke W., Wijnands, Pepijn G. J. T. B., van Wetering, Sandra, Kruisbeek, Ada M., Hooijberg, Erik, Scheffer, George L., Scheper, Rik J., and de Gruijl, Tanja D.
- Published
- 2012
- Full Text
- View/download PDF
3. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
- Author
-
de Gruijl, Tanja D., van den Eertwegh, Alfons J. M., Pinedo, Herbert M., and Scheper, Rik J.
- Published
- 2008
- Full Text
- View/download PDF
4. Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
- Author
-
van Pul, Kim M., Fransen, Marieke F., van de Ven, Rieneke, and de Gruijl, Tanja D.
- Subjects
LYMPH nodes ,T cells ,DENDRITIC cells ,TUMOR microenvironment ,IMMUNOTHERAPY - Abstract
Immune checkpoint blockade (ICB) has changed the therapeutic landscape of oncology but its impact is limited by primary or secondary resistance. ICB resistance has been related to a lack of T cells infiltrating into the tumor. Strategies to overcome this hurdle have so far focused on the tumor microenvironment, but have mostly overlooked the role of tumor-draining lymph nodes (TDLN). Whereas for CTLA-4 blockade TDLN have long since been implicated due to its perceived mechanism-of-action involving T cell priming, only recently has evidence been emerging showing TDLN to be vital for the efficacy of PD-1 blockade as well. TDLN are targeted by developing tumors to create an immune suppressed pre-metastatic niche which can lead to priming of dysfunctional antitumor T cells. In this review, we will discuss the evidence that therapeutic targeting of TDLN may ensure sufficient antitumor T cell activation and subsequent tumor infiltration to facilitate effective ICB. Indeed, waves of tumor-specific, proliferating stem cell-like, or progenitor exhausted T cells, either newly primed or reinvigorated in TDLN, are vital for PD-1 blockade efficacy. Both tumor-derived migratory dendritic cell (DC) subsets and DC subsets residing in TDLN, and an interplay between them, have been implicated in the induction of these T cells, their imprinting for homing and subsequent tumor control. We propose that therapeutic approaches, involving local delivery of immune modulatory agents for optimal access to TDLN, aimed at overcoming hampered DC activation, will enable ICB by promoting T cell recruitment to the tumor, both in early and in advanced stages of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression.
- Author
-
López González, Marta, Oosterhoff, Dinja, Lindenberg, Jelle J., Milenova, Ioanna, Lougheed, Sinead M., Martiáñez, Tania, Dekker, Henk, Quixabeira, Dafne Carolina Alves, Hangalapura, Basav, Joore, Jos, Piersma, Sander R., Cervera-Carrascon, Victor, Santos, Joao Manuel, Scheper, Rik J., Verheul, Henk M.W., Jiménez, Connie R., Van De Ven, Rieneke, Hemminki, Akseli, Van Beusechem, Victor W., and De Gruijl, Tanja D.
- Subjects
DENDRITIC cells ,IMMUNOSUPPRESSION ,TUMOR microenvironment ,T cells ,GENETIC transduction ,INTERLEUKIN-10 ,CELL differentiation ,GLYCOGEN synthase kinase-3 ,CANCER immunotherapy - Abstract
In patients with cancer, the functionality of Dendritic Cells (DC) is hampered by high levels of tumor-derived suppressive cytokines, which interfere with DC development and maturation. Poor DC development can limit the efficacy of immune checkpoint blockade and in vivo vaccination approaches. Interference in intracellular signaling cascades downstream from the receptors of major tumor-associated suppressive cytokines like IL-10 and IL-6, might improve DC development and activation, and thus enhance immunotherapy efficacy. We performed exploratory functional screens on arrays consisting of >1000 human kinase peptide substrates to identify pathways involved in DC development and its inhibition by IL-10 or IL-6. The resulting alterations in phosphorylation of the kinome substrate profile pointed to glycogen-synthase kinase-3β (GSK3β) as a pivotal kinase in both DC development and suppression. GSK3β inhibition blocked human DC differentiation in vitro, which was accompanied by decreased levels of IL-12p70 secretion, and a reduced capacity for T cell priming. More importantly, adenoviral transduction of monocytes with a constitutively active form of GSK3β induced resistance to the suppressive effects of IL-10 and melanoma-derived supernatants alike, resulting in improved DC development, accompanied by up-regulation of co-stimulatory markers, an increase in CD83 expression levels in mature DC, and diminished release of IL-10. Moreover, adenovirus-mediated intratumoral manipulation of this pathway in an in vivo melanoma model resulted in DC activation and recruitment, and in improved immune surveillance and tumor control. We propose the induction of constitutive GSK3β activity as a novel therapeutic means to bolster DC functionality in the tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. MUTZ-3 Langerhans Cell Maturation and CXCL12 Independent Migration in Reconstructed Human Gingiva.
- Author
-
Kosten, Ilona J., Spiekstra, Sander W., de Gruijl, Tanja D., and Gibbs, Susan
- Abstract
Here we describe a reconstructed full thickness human oral mucosa (gingiva) equivalent with integrated Langerhans cells (GE-LC) and use it to compare LC activation and migration from oral versus skin epithelium. The physiologically representative models consist of differentiated reconstructed epithelium (keratinocytes and Langerhans-like cells derived from the MUTZ-3 cell line) on a fibroblast-populated collagen hydrogel, which serves as a lamina propria for gingiva and dermis for skin. Topical exposure of GE-LC and the skin equivalent (SE-LC) to subtoxic concentrations of the allergens cinnamaldehyde, resorcinol and nickel sulfate resulted in LC migration out of the epithelia. Neutralizing antibody to CXCL12 blocked allergen-induced LC migration in SE-LC but not in GE-LC. Also, gingival fibroblasts secreted very low amounts of CXCL12 compared to skin fibroblasts, even when stimulated with rhTNFα or rhIL-1α. Surprisingly, cinnamaldehyde exposure of GE-LC resulted in an increase in MUTZ-3 LC and CD83 mRNA in the hydrogel but did not result in an increase in CD1a
+ cells in the collagen hydrogel (as was observed for SE-LC). These results indicate that in gingiva, upon allergen exposure, MUTZ-3 LC migrate in a CXCL12 independent manner from epithelium to lamina propria and in so doing mature by becoming CD1a- and increasing CD83+ mRNA. These physiologically relevant in vitro models, which not only are human but which also resemble specific tissues, may aid in the identification of factors regulating immune stimulation, which in turn will aid the development of therapeutic interventions for allergy and inflammation, anti-cancer vaccines as well as improving diagnostics for skin and oral allergy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.
- Author
-
Lindenberg, Jelle J., van de Ven, Rieneke, Lougheed, Sinéad M., Zomer, Anoek, Santegoets, Saskia J.A.M., Griffioen, Arjan W., Hooijberg, Erik, Van den Eertwegh, Alfons J.M., Thijssen, Victor L., Scheper, Rik J., Oosterhoff, Dinja, and de Gruijl, Tanja D.
- Subjects
INTERLEUKIN-10 ,CELL proliferation ,DENDRITIC cells ,MACROPHAGE activation ,CYTOKINES - Abstract
Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a
+ DCs found in the human skin to CD14+ CD141+ macrophage-like cells. Here, as a model of tumor-conditioned DC maturation, we functionally assessed CD14- and CD14+ DCs that matured in vitro upon exposure to IL-10. IL-10-induced CD14+ DCs were phenotypically characterized by a low maturation state as well as by high levels of BDCA3 and DC-SIGN, and as such they closely resembled CD14+ cells infiltrating melanoma metastases. Compared with DC matured under standard conditions, CD14+ DCs were found to express high levels of B7-H1 on the cell surface, to secrete low levels of IL- 12p70, to preferentially induce TH2 cells, to have a lower allogeneic TH cell and tumor antigen-specific CD8+ T-cell priming capacity and to induce proliferative T-cell anergy. In contrast to their CD14+ counterparts, CD14- monocyte-derived DCs retained allogeneic TH priming capacity but induced a functionally anergic state as they completely abolished the release of effector cytokines. Transcriptional and cytokine release profiling studies indicated a more profound angiogenic and pro-invasive signature of CD14+ DCs as compared with DCs matured in standard conditions or CD14- DCs matured in the presence of IL-10. Importantly, signal transducer and activator of transcription 3 (STAT3) depletion by RNA interference prevented the development of the IL-10-associated CD14+ phenotype, allowing for normal DC maturation and providing a potential means of therapeutic intervention. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
8. Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade.
- Author
-
Zuo, Haoxiao, van Lierop, Marie-José C., Kaspers, Jorn, Bos, Remco, Reurs, Anneke, Sarkar, Saheli, Konry, Tania, Kamermans, Alwin, Kooij, Gijs, de Vries, Helga E., de Gruijl, Tanja D., Karlsson-Parra, Alex, Manting, Erik H., Kruisbeek, Ada M., and Singh, Satwinder Kaur
- Subjects
CD47 antigen ,CANCER vaccines ,TUMOR antigens ,MYELOID cells ,ACUTE myeloid leukemia - Abstract
DCP-001 is a cell-based cancer vaccine generated by differentiation and maturation of cells from the human DCOne myeloid leukemic cell line. This results in a vaccine comprising a broad array of endogenous tumor antigens combined with a mature dendritic cell (mDC) costimulatory profile, functioning as a local inflammatory adjuvant when injected into an allogeneic recipient. Intradermal DCP-001 vaccination has been shown to be safe and feasible as a post-remission therapy in acute myeloid leukemia. In the current study, the mode of action of DCP-001 was further characterized by static and dynamic analysis of the interaction between labelled DCP-001 and host antigen-presenting cells (APCs). Direct cell–cell interactions and uptake of DCP-001 cellular content by APCs were shown to depend on DCP-001 cell surface expression of calreticulin and phosphatidylserine, while blockade of CD47 enhanced the process. Injection of DCP-001 in an ex vivo human skin model led to its uptake by activated skin-emigrating DCs. These data suggest that, following intradermal DCP-001 vaccination, local and recruited host APCs capture tumor-associated antigens from the vaccine, become activated and migrate to the draining lymph nodes to subsequently (re)activate tumor-reactive T-cells. The improved uptake of DCP-001 by blocking CD47 rationalizes the possible combination of DCP-001 vaccination with CD47 blocking therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination.
- Author
-
Horrevorts, Sophie K., Stolk, Dorian A., van de Ven, Rieneke, Hulst, Myrthe, van Het Hof, Bert, Duinkerken, Sanne, Heineke, Marieke H., Ma, Wenbin, Dusoswa, Sophie A., Nieuwland, Rienk, Garcia-Vallejo, Juan J., van de Loosdrecht, Arjan A., de Gruijl, Tanja D., van Vliet, Sandra J., and van Kooyk, Yvette
- Subjects
ANTIGENS ,APOPTOSIS ,CELL adhesion molecules ,CELL lines ,DENDRITIC cells ,LIGANDS (Biochemistry) ,MELANOMA ,PLANTS ,POLYSACCHARIDES ,CANCER vaccines ,EXOSOMES - Abstract
Tumors that lack T cell infiltration are less likely to respond to immune checkpoint inhibition and could benefit from cancer vaccination for the initiation of anti-tumor T cell responses. An attractive vaccine strategy is in vivo targeting of dendritic cells (DCs), key initiators of antigen-specific T cell responses. In this study we generated apoptotic tumor cell-derived extracellular vesicles (ApoEVs), which are potentially an abundant source of tumor-specific neo-antigens and other tumor-associated antigens (TAAs), and which can be manipulated to express DC-targeting ligands for efficient antigen delivery. Our data demonstrates that by specifically modifying the glycocalyx of tumor cells, high-mannose glycans can be expressed on their cell surface and on extracellular vesicles derived after the induction of apoptosis. High-mannose glycans are the natural ligands of dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), a dendritic cell associated C-type lectin receptor (CLR), which has the ability to efficiently internalize its cargo and direct it to both major histocompatibility complex (MHC)-I and MHC-II pathways for the induction of CD8
+ and CD4+ T cell responses, respectively. Compared to unmodified ApoEVs, ApoEVs carrying DC-SIGN ligands are internalized to a higher extent, resulting in enhanced priming of tumor-specific CD8+ T cells. This approach thus presents a promising vaccination strategy in support of T cell-based immunotherapy of cancer. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
10. Comparison of a novel CXCL12/CCL5 dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from non-sensitizers using MUTZ-3 Langerhans cells
- Author
-
Ouwehand, Krista, Spiekstra, Sander W., Reinders, Judith, Scheper, Rik J., de Gruijl, Tanja D., and Gibbs, Susan
- Subjects
- *
CELL migration , *SECRETION , *GENE expression , *LANGERHANS cells , *MYELOID leukemia , *CELL lines , *IRRITANTS (Drugs) , *DENDRITIC cells , *SALICYLIC acid , *TUMOR necrosis factors - Abstract
Abstract: As the induction of contact hypersensitivity is the result of a series of cellular processes, including maturation and migration of epidermal dendritic cells (Langerhans cells (LC)), a battery of assays based on these in vivo events might provide a robust in vitro predictability model for distinguishing sensitizers from non-sensitizers. Therefore, assays with read-out for changes in CD86 expression and CXCL8 secretion were compared with a novel functional assay based on the in vitro migratory behaviour of LC. In all three assays LC derived from the human myeloid-leukaemia-cell-line MUTZ-3 (MUTZ-LC) were used. Exposure of MUTZ-LC to a panel of five sensitizers and three non-sensitizers resulted in increased CD86 expression in only 3/5 sensitizers, but also in 1/3 non-sensitizers. In contrast, CXCL8 secretion was uniformly increased after exposure to all sensitizers, but not after exposure to non-sensitizers. In a transwell migration assay, preferential migration of sensitizer-exposed MUTZ-LC towards CXCL12 was observed (5/5 sensitizers), whereas non-sensitizer-exposed MUTZ-LC only migrated towards CCL5 (3/3 non-sensitizers). In conclusion, the novel MUTZ-LC migration assay and analysis of CXCL8 secretion proved to be more successful than analysis of CD86 in predicting sensitizers from non-sensitizers and therefore warrant further investigation in the field of in vitro assay development. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
11. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo
- Author
-
Thacker, Erin E., Nakayama, Masaharu, Smith, Bruce F., Bird, R. Curtis, Muminova, Zhanat, Strong, Theresa V., Timares, Laura, Korokhov, Nikolay, O’Neill, Ann Marie, de Gruijl, Tanja D., Glasgow, Joel N., Tani, Kenzaburo, and Curiel, David T.
- Subjects
- *
ADENOVIRUSES , *GENETIC vectors , *MICROBIAL genetic engineering , *IMMUNOREGULATION , *DENDRITIC cells , *TUMOR antigens , *CANCER vaccines , *CANCER immunotherapy , *LIGANDS (Biochemistry) , *LABORATORY dogs - Abstract
Abstract: Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of this targeted vector to induce immune responses to the tumor antigen CEA in a stringent in vivo canine model. CD40-targeted Ad5 transduced canine DCs via the CD40-CD40L pathway in vitro, and following vaccination of healthy dogs, CD40-targeted Ad5 induced strong anti-CEA cellular and humoral responses. These data validate the canine model for future translational studies and suggest targeting of Ad5 vectors to CD40 for in vivo delivery of tumor antigens to DCs is a feasible approach for successful cancer therapy. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
12. Circulating Vα24+Vβ11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients
- Author
-
van der Vliet, Hans J.J., Molling, Johan W., von Blomberg, B. Mary E., Kölgen, Wendy, Stam, Anita G., de Gruijl, Tanja D., Mulder, Chris J., Janssen, Harry L.A., Nishi, Nobusuke, van den Eertwegh, Alfons J.M., Scheper, Rik J., and van Nieuwkerk, Carin J.M.
- Subjects
- *
LIVER diseases , *DENDRITIC cells , *HEPATITIS C virus , *IMMUNE response - Abstract
Abstract: CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid α-galactosylceramide (α-GalCer, KRN7000). Previous studies have indicated that α-GalCer-induced activation of the immune system requires both CD1d expression by antigen-presenting cells as well as (normal) numbers of NKT cells. Discrepancies exist over circulating numbers of human invariant Vα24+Vβ11+ NKT cells during hepatitis C virus (HCV) infection. Here, by cross-sectional analysis and longitudinal analysis of patients undergoing effective combination antiviral therapy, we demonstrate that circulating Vα24+Vβ11+ NKT cell numbers are not decreased during active HCV infection. Importantly, as we also show that CD1d is expressed at comparable levels by peripheral blood monocytes and CD1c+ myeloid dendritic cells (DC) of healthy individuals and HCV-infected patients, these data indicate that all ingredients for evaluating the antiviral effects of the Vα24+Vβ11+ NKT cell ligand α-GalCer in HCV-infected patients are present. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.